by Mrudula Kulkarni
1 minutes
Hummingbird Bioscience Elevates Dr. Kwek and Dr. Ooi to CMO and COO Roles
Hummingbird Bioscience names Dr. Kwek as CMO and Dr. Ooi as COO, strengthening leadership team.
Lisa Ooi, PhD, and Kon Yew Kwek, BM BCh, DPhil, have been named Chief Medical Officer and Chief Operating Officer, respectively, by precision biotherapeutics startup Hummingbird Bioscience.
Chief Medical Officer Dr. Kon Yew Kwek
Kwek moves up from Senior Vice President of Clinical Development to Chief Medical Officer. He brought two decades of expertise from clinical practice, Akeso Biopharma, Eli Lilly, and IQVIA to the organisation when he joined in 2022. From Singapore, he will oversee the company's clinical development.
Kwek expressed excitement about upcoming clinical program milestones and moving additional pre-clinical research closer to the clinic.
Chief Operating Officer Dr. Lisa Ooi
Ooi advances from Senior Vice President of Strategy to Chief Operating Officer. She began working for the firm in 2022 and brings with her twenty years of expertise from the biopharma sector and Singapore's government organisations, such as the Economic Development Board, ASLAN Pharmaceuticals, Bayer, and the Agency for Science, Technology, and Research (A*STAR).
"It gives me great pleasure to spearhead the team's expansion plan into the next phase, using our robust scientific skills and unwavering dedication to comprehending tumour biology in great detail. I'm excited about what we may do in the upcoming year with our unique antibody and dual-payload ADC platform technologies, stated Ooi.
